The global market for Real World Data was valued at US$2.2 Billion in 2024 and is projected to reach US$5.4 Billion by 2030, growing at a CAGR of 15.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Real World Data market.
Segments: Component (Services, Datasets); Application (Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research, Other Applications); End-Use (Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers, Government Agencies, Other End-Uses).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global 'Real World Data' Market - Key Trends & Drivers Summarized
Is Real World Data Reshaping The Future Of Evidence-Based Decision Making?
Real World Data (RWD) is becoming a cornerstone of healthcare innovation, shifting the paradigm from controlled clinical trials to evidence drawn from real-life patient experiences. Sourced from electronic health records (EHRs), insurance claims, patient registries, wearables, and mobile health apps, RWD provides insights into treatment efficacy, safety, adherence, and outcomes across diverse populations. It allows regulators, payers, and pharmaceutical companies to understand how therapies perform outside controlled environments, supporting adaptive clinical trials, pharmacovigilance, and value-based reimbursement models. In public health, RWD informs policy decisions and tracks disease progression in real-time. As healthcare systems push for personalized, data-driven care, RWD is emerging as a strategic asset that links patient behavior with actionable clinical insights.What Technologies Are Unlocking The Full Potential Of RWD?
The explosion of health data and advances in data analytics are unlocking new frontiers for Real World Data utilization. Cloud computing, big data platforms, and AI algorithms are enabling the ingestion, harmonization, and real-time analysis of massive, heterogeneous datasets. Natural language processing (NLP) is extracting structured insights from clinical notes and unstructured EHR data. Interoperability frameworks like HL7 FHIR are improving data sharing across systems and stakeholders. Blockchain is being explored to ensure data provenance, security, and patient consent. These technologies are transforming RWD from passive records into dynamic resources that fuel drug development, population health strategies, and personalized treatment pathways. As data ecosystems mature, the quality, reliability, and regulatory acceptance of RWD are also improving.How Are Stakeholders Across The Healthcare Ecosystem Embracing RWD?
Pharmaceutical companies are integrating RWD into all stages of the drug lifecycle - from trial design and site selection to post-market surveillance and label expansion. Regulators like the FDA and EMA are increasingly relying on RWD to support approvals and monitor safety in real-world populations. Payers are using RWD to assess cost-effectiveness and inform coverage decisions. Healthcare providers are applying RWD analytics to improve care coordination, reduce readmissions, and optimize treatment protocols. Patients are also becoming key stakeholders, contributing data through apps and wearable devices while demanding transparency and control. The convergence of stakeholder interests around RWD is fostering partnerships, data consortiums, and innovation hubs that accelerate the transformation of health data into health impact.What’s Accelerating Growth In The Real World Data Market Globally?
The growth in the Real World Data market is driven by advancements in health data infrastructure, regulatory support, and end-user demand for personalized, value-based care. Technologically, improved analytics tools, cloud scalability, and interoperability standards are enabling actionable insights from vast and diverse datasets. From an end-use perspective, biopharma, payers, and health systems are leveraging RWD to drive efficiency, optimize outcomes, and meet evolving care expectations. Increased use of digital health tools, wearables, and patient engagement platforms is generating richer datasets for analysis. Regulatory initiatives supporting RWD in decision-making and policy formulation are also boosting market credibility. As global healthcare systems transition from volume to value, the ability to derive meaningful insights from real-world evidence is becoming a key competitive differentiator.Report Scope
The report analyzes the Real World Data market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Component (Services, Datasets); Application (Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research, Other Applications); End-Use (Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers, Government Agencies, Other End-Uses).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Services Component segment, which is expected to reach US$3.7 Billion by 2030 with a CAGR of a 17.7%. The Datasets Component segment is also set to grow at 12.5% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $590.5 Million in 2024, and China, forecasted to grow at an impressive 14.9% CAGR to reach $835.4 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Real World Data Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Real World Data Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Real World Data Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Aetion, Inc., Atropos Health, BEKHealth, Cerner Corporation, Clarify Health Solutions and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 42 companies featured in this Real World Data market report include:
- Aetion, Inc.
- Atropos Health
- BEKHealth
- Cerner Corporation
- Clarify Health Solutions
- ConcertAI
- Datavant
- Evidera, Inc.
- Flatiron Health, Inc.
- HealthVerity
- IBM Corporation
- ICON plc
- IQVIA Holdings Inc.
- K2view
- Merative
- Mount Sinai Health System
- Optum, Inc.
- Palantir Technologies Inc.
- PAREXEL International Corporation
- SAS Institute Inc.
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What's Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aetion, Inc.
- Atropos Health
- BEKHealth
- Cerner Corporation
- Clarify Health Solutions
- ConcertAI
- Datavant
- Evidera, Inc.
- Flatiron Health, Inc.
- HealthVerity
- IBM Corporation
- ICON plc
- IQVIA Holdings Inc.
- K2view
- Merative
- Mount Sinai Health System
- Optum, Inc.
- Palantir Technologies Inc.
- PAREXEL International Corporation
- SAS Institute Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 180 |
| Published | May 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 2.2 Billion |
| Forecasted Market Value ( USD | $ 5.4 Billion |
| Compound Annual Growth Rate | 15.9% |
| Regions Covered | Global |
